Congescor

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Congescor

Property Description
Active ingredient Bisoprolol Fumarate
Form Tablet (for oral use)
Pharmacological class β₁-Selective Adrenoceptor Blocking Agent (Beta-blocker)
General purpose Management of chronic cardiovascular conditions
Origin Synthetic Compound

What is Congescor and its Active Ingredient?

Congescor is the trade name for a prescription-only medication whose active component is Bisoprolol Fumarate. The drug is a chemically synthesized compound, formulated for oral administration, and delivered as a solid tablet. The preparation is a single-entity product that provides therapeutic action solely through the defined pharmacological profile of the Bisoprolol substance. Bisoprolol is established as a therapeutic agent in cardiovascular care.


Classification: Understanding Cardioselective Beta-Blockers

Congescor belongs to the beta-blocker class, specifically categorized as a β₁-selective adrenoceptor blocking agent, which is a type of antihypertensive and sympatholytic agent. This classification signifies that the substance is designed to selectively interfere with the effects of stress hormones like adrenaline on the cardiovascular system. A defining characteristic is its high degree of cardioselectivity. This property means its primary action is directed toward the β₁ receptors found predominantly in the heart, providing a more targeted cardiac intervention compared to earlier, non-selective agents.


General Purpose: How Congescor Supports Cardiovascular Health

The general purpose of this medication is to provide supportive and stabilizing management for various chronic cardiovascular conditions, typically utilized in adult patient groups. Its core function involves reducing the heart rate and the force of heart muscle contraction. These combined actions fundamentally lessen the overall workload and oxygen consumption of the heart. This therapeutic effect is crucial for effectively managing persistent stress on the cardiovascular system and contributing to the control of conditions such as elevated systemic blood pressure.

Regulatory References

  1. Bisoprolol Fumarate Public Assessment Report

What side effects are possible with Congescor?

The safety profile of Bisoprolol Fumarate (Congescor) is documented through formal classifications developed by regulatory authorities like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Adverse reactions are classified by frequency and by the physiological system affected.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common Bradycardia (slow heart rate), noted primarily in chronic heart failure patients.
Common Fatigue, asthenia (weakness), dizziness, headache, coldness or numbness in extremities, and gastrointestinal complaints (nausea, vomiting, diarrhea, constipation).
Uncommon Sleep disorders, depression, atrioventricular (AV) conduction disturbances, worsening of pre-existing heart failure, and bronchospasm.
Rare Hepatitis, increased liver enzymes (ALT, AST), hypersensitivity reactions (rash, pruritus), reduced tear flow, and hearing disorders.

Official Safety Constraints

Formal restrictions govern the use of this medication. It is contraindicated in severe cardiac conditions such as cardiogenic shock, second or third-degree AV block (without a pacemaker), severe bradycardia, and acute heart failure. The safety label also notes the potential for severe consequences, such as severe hypotension, when co-administered with certain calcium antagonists.

Contextual and Population Safety Notes

Specific safety considerations exist for certain groups. Caution and potential dose adjustment are required for individuals with renal or hepatic impairment. Furthermore, some common effects like fatigue and headache are documented to occur especially at the beginning of therapy and generally diminish within the first one to two weeks.

Overdose and Emergency Response

The official regulatory documents define Bisoprolol Fumarate (Congescor) overdose by listing the serious clinical and physiological consequences of exaggerated beta-blockade. The most commonly expected manifestations include severe cardiovascular effects such as bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and the onset or worsening of congestive heart failure. Non-cardiac effects documented in the official overdose profile include bronchospasm (airway constriction) and hypoglycemia (low blood sugar).

These presentations warrant an immediate and decisive response. Regulatory guidance strictly mandates that Bisoprolol Fumarate therapy must be stopped immediately upon diagnosis of overdose. Due to the potential for life-threatening complications, urgent professional medical attention is required. Management, which must be provided under medical supervision, involves providing supportive and symptomatic treatment tailored to the specific clinical presentation.

Procedural constraints noted in the labeling state that limited data suggest Bisoprolol Fumarate is not dialyzable. Specific interventions, such as the use of sympathomimetic agents to counter certain adverse effects, have been utilized in documented overdose cases. The overall regulatory profile emphasizes that any suspected overdose requires the immediate involvement of emergency medical services to stabilize critical functions and manage the severe, documented systemic risks.

Therapeutic Uses of Congescor

Quick Facts

  • Hypertension (High Blood Pressure): The medication is indicated for use in the management of high blood pressure.
  • Chronic Heart Failure: It is used as a component of the comprehensive management plan for mild to severe stable chronic heart failure.
  • Angina Pectoris: The drug may be used to support the management of certain types of chest pain associated with reduced blood flow to the heart.

Congescor (bisoprolol fumarate) is a prescription treatment used in the management of specific cardiovascular conditions. Its primary use is indicated in supporting individuals with hypertension, which is sustained high blood pressure. Controlling blood pressure is a component of a long-term strategy to reduce the potential for serious health events.

This medication also has an established role in the comprehensive treatment regimen for certain patients who are experiencing mild to severe chronic heart failure (CHF). In this context, it may be used in conjunction with other agents to help manage the symptoms associated with reduced cardiac function.

Furthermore, the treatment is utilized to help manage the symptoms of angina pectoris, which is chest discomfort that may occur when the heart muscle does not receive adequate oxygen. The drug helps to achieve stable control of heart function, which may reduce the occurrence of anginal episodes. Healthcare professionals determine if this treatment is appropriate based on individual clinical presentations and needs.

Eligibility and Restrictions for Use

Who Can and Cannot Use Congescor?

This section outlines the officially documented population eligibility rules for Congescor (Bisoprolol Fumarate) based on government regulatory labeling.

Contraindicated Populations (Absolute Exclusion)

The medicine must not be used by patients with specific severe conditions, including hypersensitivity to Bisoprolol, cardiogenic shock, acute heart failure, second- or third-degree AV block (without a pacemaker), and severe bronchial asthma or severe COPD. Use is also strictly prohibited in cases of symptomatic bradycardia (heart rate below 60 beats/min) or symptomatic hypotension.


Restricted or Not Recommended Use

Population Group Regulatory Status Limitation/Restriction
Children and Adolescents Not Recommended Safety and effectiveness have not been established in the pediatric population.
Pregnancy Not Recommended Use only if clearly necessary due to potential risks to the foetus, as documented in official labeling.
Severe Organ Impairment Restricted Use The daily dose should not exceed 10 mg for patients with severe renal impairment (creatinine clearance less than 20 mL/min) or severe hepatic impairment.
Ischaemic Heart Disease Restriction on Cessation Abrupt discontinuation is prohibited; the dose must be reduced gradually.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Element Regulatory Statement
Medicinal product categories with documented interactions: Other beta-blocking agents, Calcium Channel Blockers (non-dihydropyridine type), Antiarrhythmic Agents, Cardiac Glycosides, alpha2-receptor agonists.
Specific interacting medicines (if explicitly listed): Rifampin (Rifampicin), Verapamil, Diltiazem, Clonidine.
Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction leading to increased metabolic clearance; Pharmacodynamic interactions leading to additive effects on myocardial function and sympathetic activity.

Interaction Classifications (High-Level)

Classification Regulatory Statement
Interaction severity classification (as defined in official documents): Formal restriction (with other beta-blockers); Clinically significant interactions requiring caution (with Verapamil, Diltiazem); Interactions altering exposure (with Rifampin).

Official interaction statements:

  • Co-administration with other systemic beta-blocking agents is formally restricted in regulatory documents.
  • The use of Rifampin increases the metabolic clearance of bisoprolol, resulting in a shortened elimination half-life and reduced exposure.
  • Co-administration with non-dihydropyridine Calcium Channel Blockers (Verapamil, Diltiazem) carries the risk of additive pharmacodynamic effects, including intensified bradycardia and AV block.
  • Concurrent use with Digitalis (cardiac glycosides) results in additive effects in depressing A-V conduction.
  • If concurrent therapy with Clonidine is to be stopped, Bisoprolol must be discontinued for several days before the withdrawal of Clonidine.
  • Catecholamine-depleting drugs (e.g., Reserpine) may produce an excessive reduction of sympathetic activity when combined with Bisoprolol.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents define the product’s interaction structure primarily through pharmacodynamic interactions with other cardiovascular agents, emphasizing the additive potential for cardiac depression and conduction slowing. A key restriction is the formal regulatory prohibition on combining it with other systemic beta-blockers. The profile also documents a pharmacokinetic interaction where Rifampin alters the metabolic clearance, thereby decreasing the drug’s overall exposure.

Mechanism of Action

Congescor (Bisoprolol Fumarate) acts through highly selective pharmacological mechanisms to modulate the cardiovascular system's response to sympathetic signaling.


Selective beta1 Adrenoceptor Blockade

This domain covers the drug's core action as a competitive antagonist primarily targeting the mathbfbeta1 -adrenoceptors found in the heart muscle and pacemaker cells. By blocking the binding of endogenous catecholamines (like epinephrine), the drug interrupts the sympathetic signaling cascade, resulting in a reduction in both the heart's rate (negative chronotropy) and its contractile force (negative inotropy).


Modulation of Neurohormonal Pathways

The mechanism extends beyond the heart to key regulatory systems, specifically by blocking beta1 receptors on the juxtaglomerular cells in the kidneys. This action inhibits the release of renin, which is the rate-limiting enzyme in the Renin-Angiotensin System (RAS) cascade. This neurohormonal modulation affects systemic vascular tone.


Impact on Myocardial Oxygen Demand

The combined mechanistic effect of reducing heart rate and contractile force directly lowers the heart's overall workload. This physiological outcome results in reduced myocardial oxygen consumption due to the suppression of sympathetic overdrive.

Dosage and Administration Information

Official Administration Guidelines

The use of Congescor (bisoprolol fumarate) follows specific administration protocols for its oral tablet form. This ensures correct dose adjustment based on the condition being managed.

Instruction Detail
Route of administration Oral (swallowed with liquid)
Dosing schedule (Hypertension/Angina) Starting Dose: Typically 5 mg once daily; max dose is 20 mg once daily.
Dosing schedule (Chronic Heart Failure) Starting Dose: 1.25 mg once daily. Requires gradual titration over several weeks/months to a maximum target of 10 mg once daily.
Timing in relation to meals May be taken with or without food, typically in the morning.
Age-group administration rules Use in children is not recommended; dose adjustment for older adults is only necessary if severe organ impairment is present.
Missed-dose rules Take the missed dose as soon as remembered; if it is near the next scheduled dose, skip the missed dose and do not double the amount.
Special procedural conditions The tablet must be swallowed whole and not chewed. Treatment for heart failure must be initiated only when the patient is clinically stable.

Instruction Classifications

Classification Detail
Administration method type Oral, solid tablet
Frequency pattern Once daily (q.d.).
Standardization Governed by standardized instructions for clinical use.
Use-context constraints Discontinuation: Must be gradually reduced (tapered) over approximately one week; abrupt withdrawal is prohibited.

Resulting Procedural Structure

Official step sequence:

  • Initiation: Begin with the specific low dose defined by the condition, taken once daily.
  • Titration: For heart failure, increase the dose gradually in successive steps, requiring close monitoring during each change.
  • Cessation: If therapy must be stopped, the dosage must be progressively reduced over a scheduled period to minimize risk.

Connection to the overall use protocol: The protocol establishes Congescor as a long-term, once-daily oral therapy with two distinct dosing patterns depending on the indication: a fixed-dose maintenance for hypertension or a mandatory, controlled titration for stable chronic heart failure. This structure, along with the required gradual tapering for discontinuation, defines the standardized approach to administering the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Congescor

The research base for Congescor (Bisoprolol Fumarate) has primarily utilized large-scale, randomized, double-blind, placebo-controlled trials to examine its use across major cardiovascular conditions. These studies track long-term outcomes, including all-cause mortality, and were applied in studies examining patient-reported experiences and clinical events.


Evidence for use in Chronic Heart Failure

Research studies, such as the CIBIS trials, were structured to examine the potential difference in all-cause mortality and the frequency of hospitalization for heart failure in adult patients with stable disease and reduced cardiac function. Findings describe patterns observed in these studies, which often focused on the time elapsed until the occurrence of specific events being tracked. The research also examined functional measures, such as the Left Ventricular Ejection Fraction (LVEF), when compared to an inactive placebo in the studied patient groups.

Evidence for use in Hypertension (High Blood Pressure)

Congescor was evaluated in randomized, double-blind, placebo-controlled trials that provided data for regulatory review, examining the context of blood pressure management. These studies monitored outcomes by measuring changes in both Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) over short-to-intermediate time intervals. Research described patterns related to blood pressure changes and resting heart rate in adults with mild-to-moderate high blood pressure.

Evidence for use in Angina Pectoris

The research in stable angina utilized randomized comparative trials against other established anti-anginal drugs. Studies examined outcomes related to physical discomfort by focusing on measures such as the frequency of self-reported angina attacks and the consumption of nitrate medication. Functional measures, including exercise tolerance time, were also monitored in populations with stable angina and co-occurring hypertension.


What is Still Uncertain about the Congescor Research

The existing evidence landscape highlights areas where data remains limited. For instance, dedicated, long-term RCTs that specifically explore outcomes related to major cardiovascular events in hypertension often rely on meta-analyses of the entire drug class. Data for certain groups remain insufficient, such as those for pregnant populations or children, as core pivotal trials focused on broad adult populations. Certainty remains low regarding the absolute personal outcome for any given patient, as findings describe group patterns, not personal predictions.

Key Studies & References Public Assessment Report (PAR) for Bisoprololfumaraat 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, and 10 mg film-coated tablets (EMA/Hexal Assessment)

Frequently Asked Questions (FAQ)

Common questions about Congescor (FAQ)


Q: How does Congescor differ from other common heart medications?

A: According to official product information, Congescor is specifically classified as a beta-1 selective adrenoceptor blocker. This means its primary action is targeted at specific receptors in the heart, helping to reduce the heart's workload. This mechanism differs from other common heart medications, such as calcium channel blockers or diuretics, which act on different systems in the body.


Q: What are the most serious side effects listed in the official documents for Congescor?

A: Regulatory documents list serious adverse effects, including a dangerously slow heart rate (severe bradycardia), the worsening of pre-existing heart failure, and disturbances in the heart's electrical conduction system. These effects should be discussed with a healthcare provider immediately if they occur, as they may necessitate discontinuation or dose review.


Q: Are there long-term health effects associated with Congescor use?

A: Official documents describe Congescor as a long-term treatment intended for chronic cardiovascular conditions. Clinical research supporting the drug’s use monitored patient outcomes, including mortality and hospitalization rates, over periods of several years. Long-term use generally involves monitoring as part of the established treatment protocol.


Q: Does Congescor primarily lower blood pressure or heart rate?

A: Regulatory documents explain that the drug’s mechanism works by reducing both the heart's rate and the force of its contractions. This combined effect decreases the heart's overall workload and oxygen consumption. Consequently, this primary action leads to a reduction in systemic blood pressure.


Q: What is the difference between Congescor and a calcium channel blocker?

A: Congescor is a type of beta-blocker that works by blocking specific receptors that respond to adrenaline. In contrast, calcium channel blockers reduce how much calcium enters the muscle cells. Official regulatory documents specifically warn that combining these two classes of medicine may result in additive effects that could severely intensify cardiac depression.


Q: Does Congescor cause any known changes in body weight?

A: According to official regulatory labeling, a change in body weight is not consistently listed as a common or uncommon adverse reaction. While the label mentions potential fluid retention and swelling, substantial weight change is generally not among the frequently reported side effects summarized in the clinical trial data.


Q: How long does it typically take for Congescor to start having an effect?

A: Official product information indicates that the drug’s concentration in the bloodstream typically reaches its maximum level within two to four hours after taking the tablet. While a reduction in heart rate is measurable shortly after, the maximum therapeutic effect on blood pressure may not be noticeable until about one week into the treatment period.


Q: Do patients generally have to take Congescor permanently once they start?

A: Congescor is intended for the long-term management of chronic conditions such as high blood pressure and chronic heart failure. Official warnings emphasize that therapy must not be stopped suddenly, especially in patients with certain heart conditions. Any decision regarding the long-term use or discontinuation of the drug is governed by the regulatory requirement for a gradual dose reduction schedule.


Q: Does taking Congescor have any immediate physical sensation or feeling?

A: Official safety information does not list an immediate physical sensation as a recognized side effect that occurs immediately upon swallowing the tablet. However, certain common effects, such as fatigue or dizziness, are documented to appear especially at the start of therapy, and generally diminish within the first one to two weeks.


Q: Can Congescor be taken with common over-the-counter pain relievers like ibuprofen?

A: Official regulatory documents advise caution when combining this medication with Non-Steroidal Anti-Inflammatory Drugs (mathbfNSAIDs), which includes common over-the-counter pain relievers like ibuprofen. This is because NSAIDs may potentially reduce the blood pressure-lowering effect of Congescor.


Q: Does consuming alcohol impact the way Congescor works in the body?

A: Official patient information states that alcohol consumption may increase the risk of certain central nervous system effects. Specifically, it can intensify symptoms such as dizziness, lightheadedness, or fatigue, particularly when the user is adjusting to the medication.


Q: What is the official warning regarding taking Congescor with certain cold and flu medicines?

A: Regulatory documents contain warnings regarding interactions with sympathomimetics, which are active ingredients often found in cold and flu remedies (such as decongestants). Combining these substances can potentially increase blood pressure and heart rate, which may counteract the therapeutic effects of Congescor.


Q: Can a person with diabetes be prescribed Congescor?

A: The use of Congescor in patients with diabetes is addressed in official warnings from regulatory bodies. This guidance states that the drug may mask the warning symptoms of acute low blood sugar (hypoglycemia), particularly the rapid heartbeat that typically signals an event.


Q: What does the term 'half-life' mean in relation to how Congescor works in the body?

A: In pharmacological terms, the half-life is the time it takes for the concentration of the medication in the bloodstream to be reduced by half. According to regulatory documents, the elimination half-life for the active ingredient is approximately 9 to 12 hours. This indicates the duration over which the body processes and removes the medicine.


Q: Does Congescor have a known impact on blood sugar levels?

A: Official warnings indicate that Congescor has the potential to mask the symptoms of acute low blood sugar (mathbfhypoglycemia) in individuals who use the medicine. It does this primarily by suppressing the rapid heart rate that normally acts as a warning sign of low sugar.


Q: Is Congescor available as a generic drug or only under the brand name?

A: Government drug product databases list the active ingredient, Bisoprolol Fumarate, as available in a generic form in addition to the brand name Congescor. The availability of generic medication is regulated by health authorities to ensure they meet the same quality standards as the brand name drug.


Q: What is the safety classification of Congescor regarding driving or operating heavy machinery?

A: Official warnings and patient information advise caution regarding activities that require alertness, such as driving or operating heavy machinery. Because side effects like dizziness and fatigue may occur, especially when starting the medicine, regulatory guidance requires patients to be aware of how they react to the drug before performing such activities.


Q: Is Congescor a medication that requires the user to have regular blood tests?

A: Regulatory guidance states that patients with severe kidney (renal) or liver (hepatic) impairment should use the medication with caution. Monitoring of organ function may be required in these specific patient populations, as the drug's elimination may be reduced.

How should Congescor be stored and disposed of?

Storage and Disposal Requirements for Congescor

Storage and disposal of Congescor (Bisoprolol Fumarate) tablets must strictly follow regulatory guidance to ensure product integrity and safety.

Category Requirements
Temperature Store at controlled room temperature, typically below 25 C or 30 C (77 F or 86 F), and protect from excess heat and freezing.
Protection Keep in the original container, tightly closed, and protected from light and moisture.
Stability Do not use the product after the expiry date. For certain packaging, the shelf-life after opening is 6 months.
Child Safety Must be stored out of the sight and reach of children.
Disposal Do not throw away medication via household waste or wastewater. Dispose of unused or expired tablets according to local requirements, often by returning them to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Congescor found in:

A-Z Index: